Pfizer stock setup analysis ahead of Tuesday earnings

Earnings are tomorrow, Nov 3, 2026, before the open, and Pfizer Inc (PFE) arrives at a 52-week high. The last close was $30.52 on Oct 30 (+1.9%), at the top of its $23.62–$30.67 range. Pre-market was $30.51 as of Nov 2, 9:11 AM EST, essentially flat. Monday’s session hasn’t started yet. 

Pfizer Inc (PFE): $30.52 (Oct 30 close; market cap $173.95B) || 1M +9.78% || 3M +22.03% || YTD +22.18% || Consensus EPS $0.73, revenue $15.91B

The Expectations Bar

• Estimates keep falling. EPS consensus is down 4.06% over 30 days and 10.25% over 90 days. A lower bar helps a beat.
• Pfizer has beaten four quarters running. The Q2 EPS beat was 13.24% ($0.77 vs $0.68). Q1 was +4.17% and Q4 FY25 was +13.79%.
• Beats haven’t moved the stock much. Reactions to the last four reports ranged from -0.20% to +3.12%.
• Options imply a 3.8% move, about $1.16 either way. Pfizer has exceeded the implied move in 2 of 8 reports, most recently Apr 29, 2025 (7.9% vs 2.8%) (, Oct 27, 2026).
• Analyst views. Guggenheim (Buy, $31 target) expects revenue of $16.16B and EPS of $0.77, including a charge from the Innovent licensing deal. Cantor (Neutral, $28 target) points to the MEVPRO-1 readout and to questions about long-term growth and dividend sustainability (, Oct 22, 2026).
• Likely call topics. Guggenheim expects Prevnar (about $1.65B estimated), the roughly $4B COVID guidance, and the pipeline to dominate. The pipeline items are Phase 3 mevrometostat data in prostate cancer and amylin combination data in obesity (, Oct 13, 2026).

Chart Read (Daily)

• Trend: Price sits above every moving average. The daily 20 EMA is 29.39, the SMA 50 is 28.55 and the SMA 200 is 26.80. The technical summary gauge reads Strong Buy.
• Momentum: Daily RSI is 66.5, near but below 70. ADX is 28.8, with +DI at 32.6 against -DI at 15.1, which points to a trend with direction. MACD is positive at 0.547.
• Stretched: Williams %R is -5.9 (overbought), and price is about 4% above the 20 EMA. Stochastic RSI gives a sell signal.
• Levels: Resistance is the 30.67 high. Support is the 29.6–29.9 area (pivot 29.91, Oct 29 low 29.61), then the 20 EMA at 29.39 and the Oct 28 low at 29.22. Breaking below those would put the 28.55 SMA 50 in play.
• Mixed candles: Bearish patterns appeared on Oct 12–13 (Engulfing, Upside Gap Two Crows), but the stock has since made higher highs. ATR is only 0.57, so daily ranges have been calm.

Scenarios

• Bull case: A beat plus steady guidance and good pipeline news would break 30.67. Oct 30’s volume of 45.5M was the highest in weeks, which suggests buyers were positioning ahead of the print.
• Bear case: Stocks at highs going into earnings are exposed to "sell the news" moves. Soft Prevnar numbers or any dividend or growth worries could send price back to 29.4–29.6. A 3.8% drop would land near 29.36, right at the 20 EMA.
• Valuation: InvestingPro lists the stock above Fair Value (Oct 22). The yield was about 5.76% in the same article.

Levels and indicator readings are from the Oct 30 close. Pre-market prints can change at the open.